Profile data is unavailable for this security.
About the company
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
- Revenue in USD (TTM)0.00
- Net income in USD-7.07m
- Incorporated2023
- Employees9.00
- LocationMymd Pharmaceuticals Inc855 N. Wolfe Street, Suite 601BALTIMORE 21205United StatesUSA
- Websitehttps://www.mymd.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eiger Biopharmaceuticals Inc | 15.77m | -74.96m | 4.89m | 25.00 | -- | -- | -- | 0.3098 | -50.80 | -50.80 | 10.69 | -9.77 | 0.1985 | 0.0064 | 9.19 | 630,920.00 | -94.31 | -60.25 | -186.10 | -76.51 | 99.91 | -- | -475.26 | -823.59 | 0.6809 | -22.03 | 1.54 | -- | 16.98 | -- | 22.54 | -- | 10.51 | -- |
Emmaus Life Sciences Inc | 28.46m | -4.74m | 4.90m | 55.00 | -- | -- | -- | 0.1723 | -0.0931 | -0.0931 | 0.3905 | -0.6773 | 0.6349 | 0.8184 | 9.36 | 517,454.50 | -10.58 | -- | -- | -- | 93.69 | -- | -16.66 | -- | 0.1249 | 0.1426 | -- | -- | -10.77 | -- | 33.37 | -- | -- | -- |
Portage Biotech Inc | 0.00 | -144.90m | 4.95m | 7.00 | -- | 0.1545 | -- | -- | -7.96 | -7.96 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -111.60 | -19.70 | -113.27 | -26.48 | -- | -- | -- | -- | -- | -- | 0.0087 | -- | -- | -- | -520.10 | -- | -- | -- |
Applied DNA Sciences Inc | 5.52m | -12.50m | 4.96m | 53.00 | -- | -- | -- | 0.8992 | -17.13 | -17.13 | 7.67 | -0.0558 | 0.3893 | 10.38 | 4.64 | 104,110.80 | -87.15 | -88.57 | -111.09 | -121.91 | 33.98 | 44.35 | -223.89 | -113.26 | 1.54 | -- | -- | -- | -26.43 | 27.92 | -18.73 | -- | 33.80 | -- |
Processa Pharmaceuticals Inc | 0.00 | -9.83m | 5.00m | 13.00 | -- | 0.5626 | -- | -- | -6.29 | -6.29 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -87.82 | -84.35 | -102.32 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0012 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 5.05m | 9.00 | -- | 0.2234 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
Halberd Corp | 281.24k | 25.34k | 5.09m | 3.00 | 3.45 | -- | 200.51 | 18.09 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
Galera Therapeutics Inc | 0.00 | -45.75m | 5.11m | 7.00 | -- | -- | -- | -- | -0.9971 | -0.9971 | 0.00 | -2.48 | 0.00 | -- | -- | 0.00 | -115.30 | -83.69 | -142.79 | -97.54 | -- | -- | -- | -- | -- | -6.49 | 9.23 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
Pineapple Inc | 157.59k | 376.69k | 5.12m | -- | 0.6283 | -- | 13.43 | 32.47 | 0.1114 | 0.1114 | 0.0028 | -0.0318 | 0.0388 | -- | -- | -- | 9.28 | -- | 53.43 | -- | -412.55 | -- | 239.03 | -- | 0.00 | -- | -- | -- | -- | -- | -611.10 | -- | -- | -- |
Sonnet Biotherapeutics Holdings Inc | 92.74k | -8.43m | 5.14m | 12.00 | -- | 1.68 | -- | 55.37 | -5.28 | -5.28 | 0.0315 | 0.9813 | 0.0097 | -- | 0.2248 | 7,728.33 | -87.68 | -- | -194.11 | -- | -- | -- | -9,086.22 | -- | -- | -138.21 | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
HST Global Inc | 0.00 | -141.11k | 5.14m | 1.00 | -- | -- | -- | -- | -0.0269 | -0.0269 | 0.00 | -0.1193 | 0.00 | -- | -- | -- | -29,397.92 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -24.24 | -- | -- | -- | -- | -0.7858 | -- | -- | -- |
Lipella Pharmaceuticals Inc | 477.45k | -4.74m | 5.17m | 5.00 | -- | 1.87 | -- | 10.83 | -0.7633 | -0.7633 | 0.0747 | 0.3638 | 0.1232 | -- | 6.25 | 95,490.00 | -122.37 | -- | -146.33 | -- | -- | -- | -993.39 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
Helix BioMedix, Inc. | 2.07m | -2.58m | 5.23m | 8.00 | -- | 3.35 | -- | 2.53 | -15.60 | -15.60 | 12.48 | 6.95 | 0.8047 | 1.87 | 4.55 | 258,238.80 | -100.64 | -146.31 | -120.73 | -173.57 | 68.96 | 30.80 | -125.06 | -527.12 | 1.69 | -14.57 | 0.00 | -- | 122.07 | 92.80 | 67.73 | -- | -29.08 | -- |
Stemtech Corp | 4.64m | -4.08m | 5.41m | 45.00 | -- | -- | -- | 1.17 | -0.0624 | -0.0624 | 0.0619 | -0.0092 | 1.09 | 8.35 | 65.16 | 103,098.40 | -96.70 | -- | -- | -- | 76.09 | -- | -88.58 | -- | 0.1045 | -1.81 | 2.27 | -- | -- | -- | -- | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Global X Management Co. LLCas of 31 Mar 2024 | 875.93k | 37.96% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 30.35k | 1.32% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 6.56k | 0.28% |
Iroquois Capital Management LLCas of 31 Dec 2023 | 6.25k | 0.27% |
UBS Securities LLCas of 31 Mar 2024 | 1.96k | 0.09% |
Bridgecreek Investment Management LLCas of 31 Dec 2023 | 1.00k | 0.04% |
Parallel Advisors LLCas of 31 Mar 2024 | 838.00 | 0.04% |
Group One Trading LPas of 31 Mar 2024 | 459.00 | 0.02% |
Vanguard Global Advisers LLCas of 31 Mar 2024 | 310.00 | 0.01% |
BlackRock Investment Management LLCas of 31 Mar 2024 | 247.00 | 0.01% |